Paper Details

  1. Home
  2. Paper Details

A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression.

Author: RavelliD P, Tuynman-QuaH, de JongheF

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Fluoxetine and maprotiline, antidepressants, showed similar efficacy in treating major depression in 30 and 35 hospitalized patients, respectively. Both drugs were well tolerated, with the only significant difference being weight change: weight loss in the fluoxetine group and weight gain in the maprotiline group.
Paper Details　
Original Abstract of the Article :
In a six-week double-blind randomized trial, preceded by a one-week single-blind placebo treatment, the efficacy and the side-effects of fluoxetine (40-80 mg/d) (n = 30) and maprotiline (50-150 mg/d) (n = 35) were compared in hospitalized patients with DSM-III Major Depression without psychotic feat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-2007-1014440

データ提供：米国国立医学図書館（NLM）

Fluoxetine vs. Maprotiline: A Head-to-Head Comparison in Major Depression

This research delves into the [psychiatry] realm, comparing the efficacy and side effects of two commonly used antidepressants, fluoxetine and maprotiline, in treating [major depression]. The researchers conducted a [double-blind randomized trial] to assess the effectiveness of these medications in hospitalized patients with major depression without psychotic features. The study's findings provide valuable insights into the relative efficacy and safety profiles of these antidepressants.

Fluoxetine and Maprotiline: A Tale of Two Antidepressants

The study's findings suggest that both fluoxetine and maprotiline were effective in reducing depressive symptoms, although the success rates were modest. The researchers found no significant difference in efficacy between the two medications. However, a notable difference was observed in weight change, with fluoxetine associated with weight loss and maprotiline with weight gain. These findings highlight the importance of considering potential side effects when choosing an antidepressant for individual patients.

Navigating Depression: A Journey of Personalized Treatment

Depression can be a debilitating condition, and finding the right treatment is crucial for recovery. Just as a desert camel navigates its arid environment seeking sustenance, individuals with depression must navigate their own journey towards well-being. The study's findings highlight the importance of personalized treatment plans that take into account individual needs, preferences, and potential side effects. Working closely with healthcare providers is essential for finding the most effective and safe treatment approach.

Dr. Camel's Conclusion

This research provides valuable insights into the efficacy and safety of two commonly used antidepressants. Just as the desert camel adapts to its harsh environment through its unique physiological mechanisms, we too must embrace a personalized approach to depression treatment. By working closely with healthcare providers and considering individual needs, we can find the most effective and safe path towards mental well-being.

Date :
  1. Date Completed 1991-08-19
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

1852793

DOI: Digital Object Identifier

10.1055/s-2007-1014440

Related Literature

Article Analysis
・Side Effects of maprotiline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.